Trabeculectomy: Procedure, Complications, and Alternatives

Trabeculectomy is the most commonly performed incisional surgery for glaucoma and has been in use since the mid-1960s. It works by creating a small, controlled opening in the wall of the eye so that fluid can drain from inside the eye into a pocket under the thin tissue covering it, lowering the pressure that damages the optic nerve. In large studies, the procedure controls eye pressure successfully in roughly three-quarters of patients over five or more years, though what “success” means depends heavily on how strictly you define it. For many people considering the surgery or trying to understand what a surgeon has recommended, the real questions are about practical outcomes: how much pressure relief to expect, what can go wrong, how long it lasts, and how it stacks up against newer alternatives.

How the Surgery Works

The goal of trabeculectomy is to bypass the eye’s natural drainage system, which in glaucoma is either blocked or inefficient. A surgeon creates a partial-thickness flap in the sclera (the white outer wall of the eye), removes a tiny piece of tissue underneath to open a channel into the interior, and then loosely stitches the flap back down. Fluid seeps through this channel, passes under the flap, and collects beneath the conjunctiva (the clear membrane over the white of the eye), forming a small, raised blister called a filtering bleb. From there, the fluid absorbs into surrounding blood vessels. The tightness of the stitches controls how fast fluid escapes in the early days. Later, a surgeon can selectively cut stitches with a laser to fine-tune the flow.

Almost all trabeculectomies today are performed with an anti-scarring agent applied during the procedure. Mitomycin C is the most widely used. It is soaked onto the tissue for a brief period to discourage the body’s wound-healing response from sealing the new drainage pathway shut.¹ Without it, the success rate drops substantially because scar tissue tends to close the opening over time.

Long-Term Success Rates

How well trabeculectomy works depends on your time horizon and how high you set the bar. A large retrospective study of over 400 eyes found that when success was defined as pressure between 5 and 18 mmHg without serious complications, about 86% of eyes met that target at one year and about 75% at five years.² Complete success without any additional pressure-lowering drops was slightly lower at 69%. The surgery reduced eye pressure to an average of about 12 mmHg, and over 90% of eyes achieved a pressure lower than before surgery.

Looking further out, a twenty-year follow-up study reported that about 60% of eyes still had controlled pressure without any drops, and roughly 90% had good pressure control when drops were added back in.³ That study concluded that trabeculectomy is a genuine long-term solution rather than a temporary fix.

When researchers apply stricter definitions, the numbers look quite different. A study using a tough benchmark of pressure below 15 mmHg with zero medications found that only about 55% of eyes met that standard at one year, dropping to roughly 25% at the average follow-up and just over 12% at ten years.⁴ By the more forgiving measure of avoiding revision surgery, though, success was about 80% at the same average follow-up. The takeaway is that most eyes get meaningful, lasting pressure reduction, but a majority will eventually need some supplemental treatment, whether that is eye drops, laser, or a repeat procedure.

What Can Go Wrong Early On

Trabeculectomy has a real complication profile, and glossing over it does patients a disservice. In the first weeks after surgery, the most common problem is hypotony, meaning the eye pressure drops too low. One study found that hypotony occurred in about 27% of eyes, followed by fluid collecting behind the eye (choroidal detachment) in about 16%, bleeding under the conjunctiva in 13%, and blood in the front of the eye in about 12%.⁵ Bleb leaks occurred in about 9% of cases. Most of these complications resolve with conservative management, though some require additional intervention.

Hypotony can also cause the front chamber of the eye to become shallow or flat. In a study of 52 patients who developed hypotony after trabeculectomy, over half had a mildly shallow chamber, and about 40% had a moderately shallow one.⁶ With appropriate management, eye pressure typically recovered to normal levels, though a quarter of those patients still needed pressure-lowering drops at three months.

Late Complications and Infection Risk

The bleb that makes trabeculectomy work also creates a permanent vulnerability. Because the conjunctiva over the bleb is thinner than normal tissue, it can develop leaks months or years later. In a study following nearly 240 eyes after trabeculectomy with mitomycin C, about 8% developed a bleb leak, about 2% had blebitis (infection of the bleb itself), and roughly 3% developed endophthalmitis, a serious infection inside the eye.⁷ The estimated five-year probability of developing at least one of these complications was about 18% for bleb leaks, 6% for blebitis, and about 8% for endophthalmitis.

These infections are uncommon in the grand scheme but can be devastating when they occur. Endophthalmitis, in particular, can severely impair vision. The use of mitomycin C, while critical for surgical success, is also linked to a higher rate of late infections. One large single-center review found that the rate of late endophthalmitis was about 0.7% in eyes treated with mitomycin C compared with zero cases among thousands of eyes that had trabeculectomy without it.⁸ Other factors that raise infection risk include a history of bleb leaks, chronic eyelid-margin inflammation, and certain glaucoma subtypes like pigmentary or juvenile glaucoma.⁹

Why Trabeculectomies Fail

The body’s healing response is both necessary and, in this context, the enemy. After surgery, the tissue around the new drainage channel naturally tries to repair itself by laying down scar tissue. When that scarring goes too far, it seals the pathway and the bleb flattens, and the pressure climbs back up. This process of subconjunctival fibrosis is the leading cause of trabeculectomy failure.¹⁰ Research into the molecular details has identified specific growth factors and inflammatory signals that drive the scarring process, and elevated levels of these markers in the tissue around the bleb predict which eyes will scar excessively.¹¹

Several patient-level factors independently raise the risk of failure. The Advanced Glaucoma Intervention Study found that younger age, higher preoperative pressure, diabetes, and any postoperative complication all increased the chance that the surgery would eventually fail.¹² Younger patients heal more aggressively, which in this case works against them. A separate study looking at a Cuban population found that having a previous trabeculectomy, very high preoperative pressure (above 31 mmHg), Black race, and advanced-stage glaucoma each substantially raised the failure risk, and combinations of these factors compounded the danger.¹³

When a bleb shows signs of failing, surgeons have options to try to revive it. Laser suture lysis, where remaining stitches are cut with a laser to increase drainage, is one tool. Injections of 5-fluorouracil (another anti-scarring agent) around the bleb, sometimes with needling to break up scar tissue, can also help.¹⁴ These rescue efforts do not always work, and repeat surgery is sometimes unavoidable.

Effects on Vision

One thing that catches many patients off guard is a temporary dip in vision after trabeculectomy. It can be significant: one study found that more than half of eyes experienced some degree of transient vision loss, with the more severe cases taking an average of about 11 to 12 weeks to recover.¹⁵ Permanent vision loss, though much rarer, occurred in about 8% of eyes in that study. Of those, about half were mild-to-moderate and half were severe.

The early postoperative period is the worst for visual acuity. Another study tracking patients found a notable dip at one week that improved over the following months.¹⁶ For eyes that develop hypotony, the timeline is similar: vision tends to return to its baseline level by about six months once pressure stabilizes.¹⁷ Patients need to know going in that their vision will likely get worse before it gets better, and that the recovery can take months rather than days.

Cataract Formation After Surgery

Trabeculectomy accelerates cataract development. This is not a rare side effect but a well-established consequence. The AGIS trial found that a first trabeculectomy raised the risk of cataract by about 78% overall, and when postoperative complications occurred, the risk roughly doubled compared to eyes that did not have complications.¹⁸ Marked inflammation after surgery and a flat anterior chamber were the specific complications most strongly linked to cataract formation.

Even without major complications, subtle lens changes can start surprisingly early. One study documented measurable cataract changes within the first month after trabeculectomy with mitomycin C, with those changes gradually intensifying over the following year.¹⁹ In a separate study, vision in operated eyes dropped by an average of two Snellen lines due to cataract progression, compared with fellow untreated eyes.²⁰ For younger patients, this may not matter much for years. For patients who already have early lens changes, it often means cataract surgery will be needed sooner than it otherwise would have been.

How Trabeculectomy Compares to Tube Shunts

The biggest head-to-head comparison between trabeculectomy and tube shunt implants comes from the Tube Versus Trabeculectomy (TVT) study. At five years, both procedures achieved similar average pressure reductions, with the tube group averaging about 14.4 mmHg and the trabeculectomy group about 12.6 mmHg. But the failure rate told a different story: the cumulative probability of failure was about 30% for tubes and 47% for trabeculectomy, and the reoperation rate was 9% for tubes versus 29% for trabeculectomy.²¹ It is worth noting that the TVT study enrolled patients who had already had prior eye surgery, so these results do not necessarily apply to first-time surgery in a treatment-naive eye.

A broader systematic review comparing different implant types to trabeculectomy found that the picture varies by device. Ahmed and Ex-PRESS implants produced similar pressure reductions to trabeculectomy with fewer adverse events. Baerveldt implants did not lower pressure quite as effectively but had better qualified success rates and lower rates of some complications like bleb leaks and hypotony, though they brought their own risks such as double vision and tube erosion.²² For uveitic glaucoma specifically, tube implants and trabeculectomy lower pressure about equally, but tubes carry higher rates of cystoid macular edema and revision surgery, while trabeculectomy is more likely to speed up cataract progression.²³

Trabeculectomy Versus Micro-Invasive Glaucoma Surgery

Micro-invasive glaucoma surgery (MIGS) has gained popularity because these procedures are quicker, cause less tissue disruption, and generally have milder side-effect profiles. The trade-off, however, is in the size of the pressure reduction. A meta-analysis found that trabeculectomy achieves about 2 mmHg more pressure reduction than MIGS procedures.²⁴ MIGS patients needed fewer medications afterward and had a higher rate of complete success (no drops at all), but trabeculectomy had a higher rate of qualified success (good pressure whether or not drops were needed). MIGS procedures also had about half the odds of significant vision loss or conjunctival bleeding compared to trabeculectomy.

A smaller comparative study found that quality of life six months after surgery did not differ between the two approaches, even though pressure was significantly lower in the trabeculectomy group at both six weeks and three months.²⁵ This matters because MIGS patients had significantly less early vision loss and required fewer medications. For people with moderate glaucoma, MIGS may provide enough pressure control with a gentler recovery. For advanced disease where every millimeter of mercury matters, trabeculectomy remains the more powerful tool.

Quality of Life After Surgery

Patients often want to know what normal life looks like after trabeculectomy. The first month is the hardest. A study tracking health-related quality of life found a meaningful dip in the first month after surgery, affecting physical functioning, social activities, and the ability to carry out daily roles.²⁶ By three months, quality of life had generally returned to preoperative levels. The primary driver of that early dip was reduced visual acuity in the operated eye.

Longer-term quality-of-life data is more mixed. One study found that overall vision-related quality of life was stable at 12 months, and mental health scores actually improved, possibly reflecting relief from the burden of daily eye drops and worry about uncontrolled pressure.²⁷ However, scores related to general health and role difficulties declined in that same study, suggesting that even when the eye is doing well, the surgery and its aftermath take a broader toll on some patients. At five years, a randomized trial comparing trabeculectomy to Baerveldt tube implants found that vision-related quality of life had declined in both groups, with no meaningful difference between them.²⁸ That decline likely reflects glaucoma’s progressive nature rather than a specific surgical harm.

Choosing Anesthesia

Trabeculectomy can be done under general anesthesia, local injection anesthesia (retrobulbar or peribulbar blocks), or sub-Tenon’s local anesthesia. A study comparing these approaches found no significant difference in surgical outcomes, including final pressure, need for medications afterward, or visual acuity.²⁹ Procedures done under general anesthesia tended to be slightly shorter, likely because local anesthesia requires extra time for the block to work and for the patient to be comfortable. There is a theoretical concern that needle-based local blocks placed behind the eye could damage the optic nerve, particularly in advanced glaucoma where the nerve is already fragile.³⁰

Some surgeons perform trabeculectomy under topical anesthesia alone, using only numbing eye drops. A comparison of topical versus retrobulbar anesthesia found that while patients in the topical group reported slightly more postoperative pain on average and used more intravenous sedation during the procedure, the difference in pain scores was small and neither group had high levels of discomfort.³¹ The choice usually comes down to surgeon preference, patient anxiety, and the complexity of the case.

Cost and Value Over a Lifetime

Glaucoma treatment is expensive whether or not you have surgery, because the alternative is decades of daily eye drops that are not cheap. An economic analysis comparing trabeculectomy, tube implants, and ongoing medical treatment found that the five-year cost of medical treatment alone averaged about $6,200, compared with about $7,900 for trabeculectomy and about $10,100 for a tube shunt.³² The five-year probability of blindness was about 4% for both surgical options and 15% for medication alone, making trabeculectomy the better value over time at roughly $8,300 per quality-adjusted life-year gained compared to medical treatment.

A UK-based trial (the TAGS study) reached a similar conclusion from a different angle. At two years, trabeculectomy was not cost-effective compared with drops at the standard UK willingness-to-pay threshold. But when projected over a patient’s remaining lifetime, surgery became cost-effective with about a 73% probability of being good value for money, because the upfront surgical cost is eventually offset by decades of reduced medication use and better pressure control.³³ For younger patients diagnosed with advanced glaucoma, where the treatment horizon stretches 30 or 40 years, the economic argument for early surgery is strongest.

Trabeculectomy in Children

Pediatric glaucoma is a different beast. Children heal aggressively, which makes scarring after trabeculectomy a bigger problem than it is in adults. Success rates tend to be lower and decline faster. One study of children undergoing trabeculectomy as their first surgery found success rates of about 72% at one month but only about 61% by the most recent follow-up, with choroidal detachment and hypotony being the most common complications.³⁴ Postoperative complications were the strongest predictor of failure in these children.

In congenital glaucoma, surgeons sometimes combine trabeculectomy with trabeculotomy (opening the drainage canal from the inside) to improve the odds. A study of this combined approach in a West African population reported that about 79% of eyes achieved good pressure control, but Kaplan-Meier analysis showed success declining steeply, from about 94% at three months to about 33% at 18 months.³⁵ The rapid falloff underscores how challenging it is to maintain a functioning bleb in young, actively healing tissue. For many pediatric cases, angle surgery or tube implants are preferred as a first-line approach, with trabeculectomy reserved for when those options fail.

Biodegradable Implants as an Alternative to Mitomycin C

Because mitomycin C increases the long-term risk of bleb-related infections, researchers have explored safer anti-scarring strategies. One such approach is Ologen, a biodegradable collagen matrix placed over the trabeculectomy site to act as a physical scaffold that guides wound healing and reduces disorderly scar formation. A systematic review comparing Ologen to mitomycin C found the collagen implant to be safe and effective, but without clear advantages over mitomycin C overall.³⁶ However, a five-year study told a more optimistic story, finding that Ologen was associated with higher rates of both complete and overall surgical success compared with mitomycin C, with no difference in complication rates.³⁷ A 24-month randomized trial found similar success rates between the two, noting that Ologen produced higher blebs.³⁸ Whether Ologen will eventually replace mitomycin C remains an open question. The evidence so far suggests it is a viable alternative, especially for patients at higher infection risk, but it has not yet displaced the standard approach in most surgical practices.